157 related articles for article (PubMed ID: 35227619)
21. Overlapping biosimilar and originator follitropin alfa preparations: How much closer can they get?
de Mora F; Howles CM
Drug Discov Today; 2022 Aug; 27(8):2071-2075. PubMed ID: 35490965
[TBL] [Abstract][Full Text] [Related]
22. Outcome from consecutive assisted reproduction cycles in patients treated with recombinant follitropin alfa filled-by-bioassay and those treated with recombinant follitropin alfa filled-by-mass.
Balasch J; Fábregues F; Peñarrubia J; Creus M; Manau D; Vidal E; Casamitjana R; Vanrell JA
Reprod Biomed Online; 2004 Apr; 8(4):408-13. PubMed ID: 15149563
[TBL] [Abstract][Full Text] [Related]
23. The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles.
Yang C; Dong N; Li F; Ji Y; Pan Y; She H
J Ovarian Res; 2022 Jun; 15(1):74. PubMed ID: 35729654
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials.
Conforti A; Esteves SC; Humaidan P; Longobardi S; D'Hooghe T; Orvieto R; Vaiarelli A; Cimadomo D; Rienzi L; Ubaldi FM; Zullo F; Alviggi C
Reprod Biol Endocrinol; 2021 Jun; 19(1):91. PubMed ID: 34154604
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years.
Bielfeld AP; Schwarze JE; Verpillat P; Lispi M; Fischer R; Hayward B; Chuderland D; D'Hooghe T; Krussel JS
Reprod Biomed Online; 2024 Jun; 48(6):103725. PubMed ID: 38593745
[TBL] [Abstract][Full Text] [Related]
26. The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review.
Velthuis E; Hubbard J; Longobardi S; D'Hooghe T
Adv Ther; 2020 Dec; 37(12):4831-4847. PubMed ID: 33058045
[TBL] [Abstract][Full Text] [Related]
27. Fine-tuning the dose of recombinant human follicle-stimulating hormone alfa to individualize treatment in ovulation induction and ovarian stimulation cycles: a real-world database analysis.
Martini AE; Beall S; Ball GD; Hayward B; D'Hooghe T; Mahony MC; Collares F; Catherino AB
Front Endocrinol (Lausanne); 2023; 14():1195632. PubMed ID: 37727455
[TBL] [Abstract][Full Text] [Related]
28. Patient evaluation of the use of follitropin alfa in a prefilled ready-to-use injection pen in assisted reproductive technology: an observational study.
Welcker JT; Nawroth F; Bilger W
Reprod Biol Endocrinol; 2010 Sep; 8():111. PubMed ID: 20843323
[TBL] [Abstract][Full Text] [Related]
29. Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment.
Agostinetto R
Reprod Biol Endocrinol; 2009 May; 7():48. PubMed ID: 19450267
[TBL] [Abstract][Full Text] [Related]
30. Routine use of r-hFSH follitropin alfa filled-by-mass for follicular development for IVF: a large multicentre observational study in the UK.
Lass A; McVeigh E;
Reprod Biomed Online; 2004 Dec; 9(6):604-10. PubMed ID: 15670403
[TBL] [Abstract][Full Text] [Related]
31. Recombinant Human Follicle-Stimulating Hormone in Controlled Ovarian Hyperstimulation with Assisted Reproductive Technology in China: A Cost-Effectiveness Analysis.
Li H; He W; Lin H; Du A; Zhang X; Yang H; Qu S
Risk Manag Healthc Policy; 2024; 17():1387-1394. PubMed ID: 38828103
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35-40 years: A German database study.
Bielfeld AP; Schwarze JE; Verpillat P; Lispi M; Fischer R; Hayward B; Chuderland D; D'Hooghe T; Krussel JS
Best Pract Res Clin Obstet Gynaecol; 2023 Jul; 89():102350. PubMed ID: 37320996
[TBL] [Abstract][Full Text] [Related]
33. XM17 Follitropin Alfa (Ovaleap(®)): A Review in Reproductive Endocrine Disorders.
Hoy SM
BioDrugs; 2016 Aug; 30(4):379-86. PubMed ID: 27342604
[TBL] [Abstract][Full Text] [Related]
34. A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective.
Grynberg M; Murphy C; Doré C; Fresneau L; Paillet S; Petrica N; Frédérique M; Ravonimbola H
J Med Econ; 2018 Nov; ():1-15. PubMed ID: 30461330
[TBL] [Abstract][Full Text] [Related]
35. Clinical Efficacy of Follitropin Alfa in GnRH-Antagonist Protocols: A Prospective Observational Phase IV Study on the Use of Biosimilar Follitropin Alfa r-hFSH in Assisted Reproductive Technology in a Routine Care Setting.
Griesinger G; Schill T; Sator M; Schenk M; Krüssel JS
J Reprod Infertil; 2021; 22(2):116-124. PubMed ID: 34041008
[TBL] [Abstract][Full Text] [Related]
36. A large observational data study supporting the PROsPeR score classification in poor ovarian responders according to live birth outcome.
Lehert P; Arvis P; Avril C; Massin N; Parinaud J; Porcu G; Rongières C; Sagot P; Wainer R; D'Hooghe T
Hum Reprod; 2021 May; 36(6):1600-1610. PubMed ID: 33860313
[TBL] [Abstract][Full Text] [Related]
37. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment.
Marrs R; Meldrum D; Muasher S; Schoolcraft W; Werlin L; Kelly E
Reprod Biomed Online; 2004 Feb; 8(2):175-82. PubMed ID: 14989794
[TBL] [Abstract][Full Text] [Related]
38. A comparative, observational study evaluating dosing characteristics and ovarian response using the recombinant human follicle-stimulating hormone pen injector with small-dose dial in assisted reproductive technologies treatment in Asia: IMPROVE study.
Choi BC; Zhou C; Ye H; Sun Y; Zhong Y; Gong F; Sini I; Abramova N; Longobardi S; Hickey M; D'Hooghe T
Reprod Biol Endocrinol; 2022 Jan; 20(1):15. PubMed ID: 35039049
[TBL] [Abstract][Full Text] [Related]
39. An updated meta-analysis comparing the efficacy and safety of biosimilar medicinal products to the original follitropin alfa.
Budani MC; Fensore S; DI Marzio M; Tiboni GM
Minerva Obstet Gynecol; 2024 Feb; 76(1):70-79. PubMed ID: 36534054
[TBL] [Abstract][Full Text] [Related]
40. Use of a recombinant human follicle-stimulating hormone:recombinant human luteinizing hormone (r-hFSH:r-hLH) 2:1 combination for controlled ovarian stimulation during assisted reproductive technology treatment: A real-world study of routine practice in the Russian Federation.
Koloda Y; Korsak V; Rozenson O; Anshina M; Sagamonova K; Baranov I; Yakovenko S; D'Hooghe T; Ershova A; Lispi M
Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):134-148. PubMed ID: 35216907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
